Application of autologous multipotent mesenchymal stromal cells for correction of liver function in patients suffering from alcoholic liver cirrhosis

Abstract

Clinical experience of application of autologous multipotent mesenchymal stromal cells in treatment of patient suffering from liver cirrhosis of alcoholic etiology is presented. A special feature is that the hepatocyte precursors were isolated directly from the patient’s liver tissue. The patient underwent laparoscopic surgery to obtain the largest volume of material and to be able to visually control the tissue sampling with minimal fibrotic changes. After liver tissue sampling, the patient was discharged for outpatient treatment in a satisfactory condition. Subsequently, the patient was re-admitted to the hospital. During repeated hospitalization, multipotent mesenchymal stromal cells in the amount of 20 million were injected into the arterial bed of the liver using x-ray endovascular technique. In the control study, 6 months after treatment, according to the 13C-metacetin test, normalization of liver function, regression of portal hypertension, and an increase in platelet levels were noted. There were no complications during this treatment. Treatment of patients suffering from cirrhosis of the liver is quite a serious and complex task. As a rule, the patient learns about his diagnosis already in the presence of complications, when the liver function is already significantly impaired. The propensity of the population to alcoholism leads to the formation of fibrosis, and subsequently cirrhosis of the liver. The absence of anti-fibrotic drugs contributes to the implementation of research to find alternative methods of treatment for this category of patients. In General, the use of autologous multipotent mesenchymal stromal cells is an effective and promising method, and research in this direction should be continued.

Keywords

cirrhosis of the liver / cell therapy / mesenchymal stromal cells of the liver / treatment of cirrhosis of the liver / hepatic cell failure / stem cells

References

[1] Абдурахманов, Д.Т. Безопасность и эффективность телапревира в лечении хронического гепатита С у больных российской популяции, включенных в исследование по программе раннего доступа / Д.Т. Абдурахманов [и др.] // Росс. журн. гастроэнтерологии, гепатологии, колопроктологии. – 2014. – Т. 24, № 1. – С. 39–46.

[2] Бакулин, И.Г. 13С-метацетиновый дыхательный тест при хронических заболеваниях печени: результаты исследования серии случаев / И.Г. Бакулин [и др.] // Фарматека. – 2018. – № 9 (362). – С. 42–47.

[3] Бакулин, И.Г. Актуальные вопросы противовирусной терапии хронических гепатитов В и С // Экспер. и клин. гастроэнтерология. – 2010. – № 5. – С. 3–9.

[4] Енукашвили, Н.И. Детектирование клеток, содержащих интернализованные мультидоменные магнитные наночастицы оксида железа (II, III), методом магнитно-резонансной томографии / Н.И. Енукашвили [и др.] // Журн. тех. физики. – 2020. – Т. 90, № 9. – С. 1418–1427.

[5] Коткас, И.Е. Использование клеточных технологий в лечении цирроза печени (оценка эффективности и способ визуализации введенных аутологичных мезенхимальных стволовых клеток) / И.Е. Коткас [и др.] // Наука и инновации в медицине. – 2020. – Т. 5, № 3. – С. 197–203.

[6] Ali, G. Bone marrow cells ameliorate liver fibrosis and express albumin after transplantation in CCl4-induced fibrotic liver / G. Ali, M.S. Masoud // Saudi Journal of Gastroenterology. – 2012. – Т. 18, № 4. – P. 263–267.

[7] Isakov, V.A. Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study / V.A. Isakov [et al.] // Antiviral therapy. – 2016. – Vol. 21, № 8. – P. 671–678.

[8] Iwamoto, T. Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloride-treated cirrhotic mice / T. Iwamoto [et al.] // Cell and Tissue Research. – 2013. – Vol. 351, № 3. – P. 487–495.

[9] Russo, F.P. Stem cells in liver failure. / F.P. Russo, M. Parola. // Best Practice & Research: Clinical Gastroenterology. – 2012. – Vol. 26, № 1. – P. 35–45.

[10] Seki, A. Adipose tissue-derived stem cells as a regenerative therapy for a murine steatohepatitis-induced cirrhosis model / A. Seki [et al.] // Hepatology. – 2013. – Vol. 58, № 3. – P. 1133–1142.

[11] Zhang, Z. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients / Z. Zhang [et al.] // Journal of Gastroenterology and Hepatology. – 2012. – Vol. 27, № 2. – P. 112–120.

[12] Zhang, Z. Stem cell therapies for liver failure and cirrhosis / Z. Zhang, F.S. Wang // Hepatology. – 2013. – Vol. 59, № 1. – P. 183–185.

RIGHTS & PERMISSIONS

Kotkas I.E., Masurov V.I., Bakulin I.G., Enukashvili N.I., Asadulayev S.M.